Lucy Edwardes Jones

Lucy Edwardes Jones has a diverse work experience, starting with their role as an Analyst at CIL Management Consultants from August 2015 to June 2017. Lucy then progressed to become a Senior Analyst from June 2017 to June 2018, and eventually a Manager in Healthcare from June 2018 to July 2020. In November 2020, they joined DefiniGEN as a Board Observer, and held this position until December 2022. From July 2020, Lucy went on to work as an Investor at BGF. In 2022, they took up multiple board positions at Pathfinder Medical, Elasmogen Ltd, and ENHANC3D GENOMICS, serving as a Board Director for each company. Most recently, starting from February 2023, they assumed the role of a Board Director at Maxion Therapeutics. Prior to their career at CIL Management Consultants, Lucy worked as an Assistant Brand Manager at Unilever from June 2013 to September 2013.

Lucy Edwardes Jones has pursued their education at Durham University, where they earned a Bachelor of Arts (B.A.) in History. Lucy also attended the University of Oxford for their Master of Science (M.Sc.) degree in Russian and East European Studies. The exact dates of their enrollment and graduation from both institutions are unknown.